-
1 Comment
Atreca, Inc is currently in a long term downtrend where the price is trading 36.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Atreca, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 14.4% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 8.7% to $-19M since the same quarter in the previous year.
Based on the above factors, Atreca, Inc gets an overall score of 1/5.
| Exchange | PINK |
|---|---|
| CurrencyCode | USD |
| ISIN | US04965G1094 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 4M |
|---|---|
| Target Price | 2 |
| PE Ratio | None |
| Beta | 1.03 |
| Dividend Yield | None |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BCEL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
